News

Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer

Publish date: June 5, 2011

 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Aghajanian reported being a consultant to and receiving research funding from Genentech, manufacturer of bevacizumab, and the trial was sponsored by Genentech. Dr. Seidman reported being a consultant to Enzon and Wyeth; receiving honoraria from Abraxis BioScience, Genentech, and Genomic Health; and receiving research funding from Abraxis BioScience.

Pages

Recommended Reading

DANBIO: Anti-TNFs Do Not Up Overall Cancer Risk in Arthritis
MDedge Internal Medicine
Adjuvant Chemotherapy Delay Worsens Survival After Colorectal Surgery
MDedge Internal Medicine
Video Report: The 2011 ASCO Annual Meeting Kicks Off in Chicago
MDedge Internal Medicine
Higher Methotrexate Dose Fends Off Pediatric Leukemia Recurrence
MDedge Internal Medicine
Therapy Matched to Tumor Abnormalities Tied to Longer Survival
MDedge Internal Medicine
Video Report: Cancer Survivors Benefit from Oncology/Primary Care Collaboration
MDedge Internal Medicine
HPV-Related Oral Cancer Incidence Spikes Sharply
MDedge Internal Medicine
Exemestane Prevents 65% of Invasive Breast Cancers in Postmenopausal Women
MDedge Internal Medicine
Crizotinib Continues to Produce High Response in ALK+ NSCLC
MDedge Internal Medicine
Screening Does Not Reduce Ovarian Cancer Mortality
MDedge Internal Medicine

Related Articles